Type Public Founder William J Motto Number of employees 550 | Area served Worldwide Founded 1977 | |
 | ||
Traded as NASDAQ: VIVO
S&P 600 Component Industry Medical equipment and Life Science Key people William J. Motto (Chairman, [Executive Chairman of the Board])
John A. Kraeutler (CEO) Website www.meridianbioscience.com Stock price VIVO (NASDAQ) US$ 13.60 +0.20 (+1.49%)17 Mar, 4:00 PM GMT-4 - Disclaimer Headquarters Cincinnati, Ohio, United States Subsidiaries Meridian Life Science Inc Profiles | ||
Meridian bioscience learn how i turned 15 253 into 1 613 442 trading biotech stocks
Meridian Bioscience Inc. (Meridian)(NASDAQ: VIVO) is an international producer and distributor of a range of diagnostic test kits. The company was founded in 1976 and is headquartered in Cincinnati, Ohio. The company consists of two segments including Diagnostics and Life Science. The focused markets of the company comprise gastrointestinal and upper respiratory infections, serology, parasitology and fugal disease testing. It distributes the products mainly to healthcare companies and organizations in over 60 countries. The company has received the United States Food and Drug Administration (FDA) clearance and introduced its molecular amplification assay into the market.
Contents
- Meridian bioscience learn how i turned 15 253 into 1 613 442 trading biotech stocks
- Background
- References
Background
The company was founded by William J. Motto in 1977. At the beginning, he figured out a more efficient way to ship specimen samples to testing labs. With his ideas, he got $500 investment and set up the business based in his home in Cincinnati. This is the original form of the company. Over years of development, his business expanded and grew into Meridian.
Its product base includes testing platform and technologies, diagnostic kits and foodborne products, such as tests for Enterohemorrhagic E. coli. The testing platform was developed by DNA amplification and enzyme-relevant technologies. The company operates its business in segments including Diagnostics (U.S. and European) and Life Science. In 2010 fiscal year, the sales of diagnostic products accounted for 81% of the total sales of the company. In the same year, the company completed the acquisition of the Bioline Group.